EUVIMEDEUVIMED entdecken
Open Access

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US

Victoria Federico Paly iD, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis Hernandez iD

Journal of Comparative Effectiveness Research · 2024

DOI: 10.57264/cer-2024-0084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Victoria Federico Paly und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Pricing, Value & Access; Global Health Economics & US HEOR - Oncology, Takeda Pharmaceuticals America, Inc., Lexington, MA 02421, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Pyridines, Thymine, Trifluridine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The objective of this study was to compare adverse event (AE) management costs for fruquintinib, regorafenib, trifluridine/tipiracil (T/T) and trifluridine/tipiracil+bevacizumab (T/T+bev) for patients with metastatic colorectal cancer (mCRC) previously treated with at least two prior lines of therapy from the US commercial and Medicare payer perspectives. Materials & methods: A cost-consequence model was developed to calculate the per-patient and per-patient-per-month (PPPM) AE costs using rates of grade 3/4 AEs with incidence ≥5% in clinical trials, event-specific management costs and duration treatment. Anchored comparisons of AE costs were calculated using a difference-in-differences approach with best supportive care (BSC) as a common reference. AE rates and treatment duration were obtained from clinical trials: FRESCO and FRESCO-2 (fruquintinib), RECOURSE (T/T), CORRECT (regorafenib) and SUNLIGHT (T/T, T/T+bev). AE management costs for the commercial and Medicare perspectives were obtained from publicly available sources.

Results

From the commercial perspective, the AE costs (presented as per-patient, PPPM) were: $4015, $1091 for fruquintinib (FRESCO); $4253, $1390 for fruquintinib (FRESCO-2); $17,110, $11,104 for T/T (RECOURSE); $9851, $4691 for T/T (SUNLIGHT); $8199, $4823 for regorafenib; and $11,620, $2324 for T/T+bev. These results were consistent in anchored comparisons: the difference-in-difference for fruquintinib based on FRESCO was -$1929 versus regorafenib and -$11,427 versus T/T; for fruquintinib based on FRESCO-2 was -$2257 versus regorafenib and -$11,756 versus T/T. Across all analyses, results were consistent from the Medicare perspective.

Conclusion

Fruquintinib was associated with lower AE management costs compared with regorafenib, T/T and T/T+bev for patients with previously treated mCRC. This evidence has direct implications for treatment, formulary and pathways decision-making in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsPyridinesThymineTrifluridineAntineoplastic Combined Chemotherapy ProtocolsBevacizumabPhenylurea CompoundsBenzofuransHumansUnited StatesIrinotecanDrug CombinationsPyrrolidinesOxaliplatinMedicareCamptothecinQuinazolinesOrganoplatinum CompoundsUracilFluorouracilModels, EconomicBiological Products

Stichwörter der Autor:innen

Medicareadverse eventscolorectal cancercostsformulary decision-makinghealth economicshealthcare resource usepharmacoeconomics

Substanzen

regorafenibPyridinesThymineTrifluridineBevacizumabPhenylurea Compoundstrifluridine tipiracil drug combinationBenzofuransIrinotecanDrug Combinations

Autor:innen und Institutionen

  • Global Pricing, Value & Access; Global Health Economics & US HEOR - Oncology, Takeda Pharmaceuticals America, Inc., Lexington, MA 02421, USA.
  • Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.
  • US Medical Affairs - Oncology, Takeda Pharmaceuticals USA, Inc., Lexington, MA 02421, USA.

ORCID-Profile: Victoria Federico Paly, Luis Hernandez

Zitieren

APA

Paly, V. F., Dasari, A., Hubbard, J., Bekaii-Saab, T., Padukkavidana, T., & Hernandez, L. (2024). Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0084

Vancouver

Paly VF, Dasari A, Hubbard J, Bekaii-Saab T, Padukkavidana T, Hernandez L. Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2024-0084

BibTeX
@article{Paly2024,
  author = {Paly, Victoria Federico and Dasari, Arvind and Hubbard, Joleen and Bekaii-Saab, Tanios and Padukkavidana, Thihan and Hernandez, Luis},
  title = {Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2024},
  doi = {10.57264/cer-2024-0084}
}
Kostenlos starten →